How much MK-677 do studies give per day?
| Source | Form | Strength |
|---|---|---|
| FDA briefing, products proposed to it | Oral capsules or tablets | 10 mg and 25 mg1 |
| FDA briefing, products found on websites | Capsules; tablets; injection; powder; liquid | Capsules 10, 12.5, 20 and 25 mg; tablets 20 mg; injection 64 mg/mL; powder 1 g; liquid 17, 25, 33 and 67 mg/mL1 |
| One outsourcing facility, 2019 and 2020 | Compounded capsule | 25 mg1 |
| TGA, 'Pharmatech' capsules | Capsule | 15 mg on the label2 |
The FDA's briefing summarises the human trials as fixed single or multiple doses of 2 mg to 50 mg per day, or weight-based doses of 0.2 to 0.8 mg/kg/day, with study durations up to 2 years.1
Strengths and approval status
The table is set at the top of the page
The FDA says ibutamoren mesylate, also known as MK-677, is not a component of an FDA-approved drug and has no applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph.1 The TGA says no product containing ibutamoren is approved for supply in Australia.2
What the trials gave per day
The FDA briefing sets the route as oral for its evaluation unless otherwise noted, and the longest trial (Nass, 2008) gave MK-677 as tablets once daily.13 Timing differed: between 7 and 9 AM in the longest trial (Nass, 2008), and at bedtime in a sleep trial (Copinschi, 1997) and a 7-day trial in young men (Copinschi, 1996).3145
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Healthy older adults (Chapman, 1996)6 | 2, 10 or 25 mg once daily, or placebo | Thirty-two, aged 64-81 | 14 and 28 days |
| Sleep, young and older adults (Copinschi, 1997)4 | Bedtime: 5 or 25 mg, or placebo, in crossover (young); 2 then 25 mg (older) | Eight young (18-30), six older (65-71) | 7 and 14 days per period |
| GH-deficient adults (Chapman, 1997)7 | Once daily by mouth: placebo then 10 mg in crossover (four men), or 10 mg then 50 mg in a rising-dose sequence (five men) | Nine severely GH-deficient men aged 17-34 | 4 days per period, two periods |
| GH-deficient children (Codner, 2001)8 | 0.2 or 0.8 mg/kg per day, with placebo on the alternate 7 days in the 0.2 mg/kg groups, then 0.8 mg/kg on day 15 for all | 18 prepubertal children | 7 to 8 days |
| Postmenopausal women (Murphy, 2001)9 | 25 mg daily with alendronate 10 mg, 25 mg alone, alendronate 10 mg alone, or placebo, in a 3:3:1:1 ratio; the 25 mg alone and placebo groups had 25 mg with alendronate 10 mg from months 12-18 | 292 women aged 64-85 with low femoral neck BMD | 12 months of an 18-month trial |
| Bone turnover, elderly adults (Murphy, 1999)10 | Three studies: 10 or 25 mg for 2 weeks; 25 mg then 50 mg daily, 2 weeks each; 5, 10 or 25 mg for 2 weeks then 25 mg for 7 weeks; each versus placebo | 187 adults aged 65 or older: 10-12 per group; 50 healthy (30 on MK-677, 20 on placebo); 105 with functional impairment | 2 to 9 weeks |
| Healthy adults aged 60-81 (Nass, 2008)31 | 25 mg once daily, taken between 7 and 9 AM, or placebo, in a modified crossover | Sixty-five | Two years |
| Alzheimer's (Sevigny, 2008)11 | 25 mg daily, or placebo | 563 patients with mild to moderate AD | 12 months |
| Hip fracture (Adunsky, 2011)121 | 25 mg/day (62 people), or placebo (61) | 123 elderly hip fracture patients | 24 weeks; terminated early due to a safety signal of congestive heart failure in a limited number of patients |
| Haemodialysis (Campbell, 2018; registry entry NCT00395291)1314 | 25mg, crossover with placebo | 49 recruited, 26 enrolled, 22 completed | 3-month crossover; about 30 days at one pill a day |
In the 2-year trial the dose was cut back to 10 mg daily in 4 people because of raised fasting glucose or joint pain.3 An earlier hip fracture trial (Bach, 2004) of one hundred sixty-one patients aged 65 and older gave MK-0677 or placebo daily for 6 months; the FDA briefing gives the arms as 25 mg (84 people) or placebo (77).151
Storage
The FDA says the nominators' certificates of analysis gave storage as room temperature or 2-8°C, with no stated duration of stability.1 Its reviewers could not find stability or degradation data at either condition.1 From its literature search, the briefing also records a recommendation to store ibutamoren mesylate in a tightly closed container in a dry and well-ventilated place.1 The same passage says it is stable at -20°C for 4 years in powder form, while the briefing's conclusions give 3 years at -20°C in powder form.1 The searches turned up no storage figure for MK-677 after mixing.
Frequently asked questions
What did the TGA find in MK-677 capsules?
The TGA found undeclared metandienone in 'Pharmatech' MK-677 capsules whose label stated 15 mg of ibutamoren per capsule.2
How is MK-677 mixed if it comes as a powder?
The FDA briefing gives a solubility of 92 mg/mL in water and ethanol and names no mixing instructions.1
How would a dose in mg become a volume on a syringe?
The FDA briefing lists products found on websites as a 64 mg/mL injection and as 17, 25, 33 and 67 mg/mL liquid, but no saved source gives a dose measured by volume or on a U-100 syringe from any of them.1
References
- FDA. October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- TGA. Unapproved ibutamoren capsules (MK-677) found to contain undisclosed anabolic steroid. tga.gov.au
- PubMed Central. Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized, Controlled Trial. 2008. pmc.ncbi.nlm.nih.gov
- PubMed. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. 1997. pubmed.ncbi.nlm.nih.gov
- PubMed. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. 1996. pubmed.ncbi.nlm.nih.gov
- PubMed. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. 1996. pubmed.ncbi.nlm.nih.gov
- PubMed. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. 1997. pubmed.ncbi.nlm.nih.gov
- PubMed. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. 2001. pubmed.ncbi.nlm.nih.gov
- PubMed. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. 2001. pubmed.ncbi.nlm.nih.gov
- PubMed. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. 1999. pubmed.ncbi.nlm.nih.gov
- PubMed. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. 2008. pubmed.ncbi.nlm.nih.gov
- PubMed. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. 2011. pubmed.ncbi.nlm.nih.gov
- PubMed Central. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT00395291: Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients. 2012. clinicaltrials.gov
- PubMed. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. 2004. pubmed.ncbi.nlm.nih.gov